Pfizer Inc. (NYSE:PFE) Shares Sold by Leisure Capital Management

Leisure Capital Management trimmed its position in shares of Pfizer Inc. (NYSE:PFE) by 4.4% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,988 shares of the biopharmaceutical company’s stock after selling 556 shares during the quarter. Leisure Capital Management’s holdings in Pfizer were worth $345,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the company. Intact Investment Management Inc. increased its holdings in shares of Pfizer by 30.9% during the 4th quarter. Intact Investment Management Inc. now owns 438,800 shares of the biopharmaceutical company’s stock valued at $12,633,000 after purchasing an additional 103,600 shares in the last quarter. Addison Advisors LLC increased its holdings in shares of Pfizer by 11.6% during the 4th quarter. Addison Advisors LLC now owns 9,322 shares of the biopharmaceutical company’s stock valued at $268,000 after purchasing an additional 970 shares in the last quarter. Gilliland Jeter Wealth Management LLC purchased a new position in shares of Pfizer during the 4th quarter valued at approximately $962,000. Headlands Technologies LLC purchased a new position in shares of Pfizer during the 4th quarter valued at approximately $1,184,000. Finally, Citizens Financial Group Inc. RI increased its holdings in shares of Pfizer by 40.7% during the 4th quarter. Citizens Financial Group Inc. RI now owns 145,969 shares of the biopharmaceutical company’s stock valued at $4,202,000 after purchasing an additional 42,202 shares in the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Trading Up 0.6 %

Shares of PFE stock traded up $0.14 on Friday, hitting $25.40. 46,526,457 shares of the stock traded hands, compared to its average volume of 34,120,812. The firm’s 50-day moving average price is $26.96 and its two-hundred day moving average price is $28.42. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.91. The stock has a market capitalization of $143.83 billion, a PE ratio of 70.56, a PEG ratio of 1.14 and a beta of 0.61. Pfizer Inc. has a twelve month low of $25.20 and a twelve month high of $40.37.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.29. The firm had revenue of $14.25 billion for the quarter, compared to analysts’ expectations of $14.37 billion. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The company’s revenue was down 41.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.14 EPS. As a group, analysts anticipate that Pfizer Inc. will post 2.24 EPS for the current year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, June 14th. Shareholders of record on Friday, May 10th will be given a $0.42 dividend. The ex-dividend date is Thursday, May 9th. This represents a $1.68 dividend on an annualized basis and a yield of 6.61%. Pfizer’s payout ratio is currently 466.67%.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on PFE. Guggenheim began coverage on shares of Pfizer in a report on Friday, February 23rd. They set a “buy” rating and a $36.00 target price for the company. Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a report on Monday, April 15th. TD Cowen lowered shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price target for the company. in a report on Thursday, January 4th. Finally, Argus lowered shares of Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Eleven analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, Pfizer currently has a consensus rating of “Hold” and a consensus price target of $36.33.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.